BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 100 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $84,572 | -4.4% | 29,990 | 0.0% | 0.00% | – |
Q4 2023 | $88,471 | -2.5% | 29,990 | -16.4% | 0.00% | – |
Q3 2023 | $90,776 | -62.0% | 35,880 | 0.0% | 0.00% | – |
Q2 2023 | $238,961 | -46.6% | 35,880 | +49.5% | 0.00% | – |
Q1 2023 | $447,840 | -13.1% | 24,000 | 0.0% | 0.00% | – |
Q4 2022 | $515,520 | +101.4% | 24,000 | +10.6% | 0.00% | – |
Q3 2022 | $256,000 | -10.5% | 21,700 | 0.0% | 0.00% | – |
Q2 2022 | $286,000 | -66.9% | 21,700 | -47.5% | 0.00% | – |
Q1 2022 | $865,000 | -97.2% | 41,368 | -97.3% | 0.00% | -100.0% |
Q4 2021 | $30,673,000 | -0.9% | 1,508,768 | +47.9% | 0.01% | -8.3% |
Q3 2021 | $30,965,000 | +13.0% | 1,020,255 | +8.2% | 0.01% | +9.1% |
Q2 2021 | $27,411,000 | -22.2% | 943,260 | +15.6% | 0.01% | -26.7% |
Q1 2021 | $35,213,000 | +11.2% | 815,881 | +19.0% | 0.02% | 0.0% |
Q4 2020 | $31,666,000 | +23.7% | 685,411 | +16.1% | 0.02% | +7.1% |
Q3 2020 | $25,595,000 | -4.3% | 590,285 | +17.0% | 0.01% | -12.5% |
Q2 2020 | $26,739,000 | +9623.3% | 504,405 | +4000.9% | 0.02% | – |
Q1 2020 | $275,000 | – | 12,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 315,000 | $7,040,000 | 3.41% |
Ikarian Capital, LLC | 693,716 | $15,505,000 | 1.17% |
EAM Global Investors LLC | 71,838 | $1,606,000 | 0.94% |
Avidity Partners Management LP | 211,000 | $4,716,000 | 0.65% |
MOODY ALDRICH PARTNERS LLC | 79,642 | $1,780,000 | 0.54% |
Knoll Capital Management, LLC | 20,000 | $447,000 | 0.42% |
EAM Investors, LLC | 55,775 | $1,247,000 | 0.39% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 299,932 | $6,703,000 | 0.22% |
Coastal Bridge Advisors, LLC | 25,014 | $559,000 | 0.20% |
Ikarian Capital, LLC | 103,300 | $2,309,000 | 0.17% |